Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$206.44M

FY 2025 · Annual

Investing Cash Flow

$168.52M

FY 2025 · Annual

Financing Cash Flow

$77.09M

FY 2025 · Annual

+256.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Depreciation & Amortization538K594K668K631K208K
Deferred Income Tax(53K)0000
Stock-Based Compensation4.27M8.3M17.24M39.99M29.88M
Change in Working Capital(961K)(6.95M)(8.9M)22.64M(437K)
Accounts Receivables00000
Inventory00000
Accounts Payables(759K)(1.25M)(581K)2.87M71K
Other Working Capital(202K)(5.7M)(8.32M)19.76M(508K)
Other Non-Cash Items158.09M14.06M63.64M(1.78M)841K
Operating Cash Flow(75.42M)(114.9M)(163.28M)(182.94M)(206.44M)
Capital Expenditures(817K)(511K)(117K)00
Acquisitions (Net)000(775K)0
Purchases of Investments0(226.37M)(109.07M)(312.22M)(85.8M)
Sales of Investments071.87M178.17M242.44M251.17M
Other Investing Activities0(13M)(4.59M)03.15M
Investing Cash Flow(817K)(168.01M)64.39M(70.56M)168.52M
Debt Repayment000057.16M
Common Stock Issued960K0233.38M13.69M19.93M
Common Stock Repurchased00(491K)00
Dividends Paid00000
Other Financing Activities1.37M3.53M(948K)7.91M0
Financing Cash Flow293.51M115.74M231.94M21.6M77.09M
Effect of Forex Changes00000
Net Change in Cash217.27M(167.17M)133.05M(231.89M)39.17M
Free Cash Flow(76.24M)(115.41M)(163.4M)(182.94M)(206.44M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$236.9M
+ D&A$208.0K
+ Stock-Based Comp$29.9M
+ Deferred Tax$0
- Working Capital-$437.0K
+ Other Non-Cash$841.0K
= Operating Cash Flow-$206.4M
- Capex$0
= Free Cash Flow-$206.4M

Analysis

FY2025 free cash flow is -$206.4M. FCF conversion is 87.1% of net income. Operating cash flow was -$206.4M, with capex of $0. The largest bridge item is Stock-Based Comp at $29.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 30, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026
4Statement of changes in beneficial ownershipAug 21, 2026

Does NMRA generate free cash flow?

Neumora Therapeutics, Inc. Common Stock (NMRA) generated -$206.44M of free cash flow in fiscal 2025.

How much operating cash flow does NMRA produce?

Operating cash flow was -$206.44M, before capital expenditures of $0.00.